Thus, in
contrast to studies conducted without drug washout in which
azilsartan appeared about 2–20 fold more potent than these
other ARBs for blocking angiotensin II binding to human
AT1
receptors, the studies conducted after drug washout
showed azilsartan to be 30–1000 times more potent than the
competitor ARBs